Opus Genetics IRD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$106.93M-82.4% | -$49.59M+13.8% | -$68.2M-151% | -$58.28M-313% | -$58.62M-419% | ||
| $53K+130% | $53K+430% | $50K+1,567% | $37K+825% | $23K+360% | ||
| $3.95M+20.1% | $3.4M+1.1% | $3.42M+4.3% | $3.38M+9.9% | $3.29M-10.9% | ||
| —— | —— | —— | —— | —— | ||
| $1.88M+560% | $7K-96.8% | $742K+178% | $36K— | -$409K— | ||
| -$3.34M-176% | -$3.5M-160% | -$268K— | $2.43M— | $4.38M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$5K— | -$4K— | ||
| -$38.99M-35.1% | -$35.25M-37.8% | -$32.86M— | -$31.83M— | -$28.85M— | ||
| —— | $0-100% | $302.5K-66.7% | $605K0.0% | $907.5K+200% | ||
| $0-100% | $0-100% | $1.21M— | $1.21M— | $1.21M— | ||
| $7.65M+215% | $5.81M+29.1% | $5.63M-31.7% | $865K-93.5% | $2.43M-79.3% | ||
| —— | —— | —— | —— | —— | ||
| $57.15M+156% | $50.02M+1,072% | $25.91M+229% | $21.72M+68.5% | $22.36M+96.9% | ||
| —— | —— | —— | —— | -$5.37M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | $0-100% | $611.75K-66.7% | $1.22M0.0% | $1.84M+200% | ||
| $53K+130% | $53K+430% | $50K+1,567% | $37K+825% | $23K+360% | ||
| -$65.68M-2,383% | -$11.52M-16,093% | -$5.73M-30,263% | $3.79M+4,643% | $2.88M+3,496% | ||
| -$3.34M-176% | -$3.5M-160% | -$268K— | $2.43M— | $4.38M— | ||
| —— | —— | —— | $230K+115% | $481K+126% | ||
| —— | —— | —— | —— | —— | ||
| —— | $57K— | $42.75K— | $28.5K— | $14.25K— | ||
| —— | $0-100% | $7M-66.7% | $14M0.0% | $21M+200% | ||
| —— | —— | —— | —— | $1.37M— | ||
| —— | $2.3M+892% | $2.25M+528% | $1.66M+359% | $1.58M+367% | ||
| —— | $23M— | $17.25M— | $11.5M— | $5.75M— | ||
| —— | —— | —— | —— | $5.98M— | ||
| —— | —— | —— | —— | $15.52M— | ||
| —— | —— | —— | —— | —— | ||
| $198K— | $129K— | $68K— | $0— | —— | ||
| —— | $0-100% | $238.75K-66.7% | $477.5K0.0% | $716.25K+200% | ||
| —— | $1.05M— | $789K— | $526K— | $263K— | ||
| —— | —— | —— | -$5K— | -$4K— | ||
| $0— | $0— | $0-100% | $0-100% | $0-100% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Opus Genetics generate?
- Opus Genetics (IRD) generated -$39.0M in operating cash flow over the trailing twelve months.
- Where does Opus Genetics's cash flow data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
